School of Life Science and Technology, Tokyo Institute of Technology, Midori-ku, Yokohama, Japan.
SBI Pharmaceuticals Co. Ltd., Minato-ku, Tokyo, Japan.
PLoS One. 2023 Feb 9;18(2):e0281399. doi: 10.1371/journal.pone.0281399. eCollection 2023.
Angiotensin converting enzyme 2 (ACE2), an entry receptor found on the surface of host cells, is believed to be detrimental to the infectious capability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Scientists have been working on finding a cure since its outbreak with limited success. In this study, we evaluated the potential of 5-aminolevulinic acid hydrochloride (ALA) in suppressing ACE2 expression of host cells. ACE2 expression and the production of intracellular porphyrins following ALA administration were carried out. We observed the reduction of ACE2 expression and intracellular porphyrins following ALA administration. ALA suppressed the ACE2 expression in host cells which might prevent binding of SARS-CoV-2 to host cells. Co-administration of ALA and sodium ferrous citrate (SFC) resulted in a further decrease in ACE2 expression and increase in intracellular heme level. This suggests that the suppression of ACE2 expression by ALA might occur through heme production. We found that the inhibition of heme oxygenase-1 (HO-1), which is involved in heme degradation, also resulted in decrease in ACE2 expression, suggesting a potential role of HO-1 in suppressing ACE2 as well. In conclusion, we speculate that ALA, together with SFC administration, might serve as a potential therapeutic approach in reducing SARS-CoV-2 infectivity through suppression of ACE2 expression.
血管紧张素转换酶 2(ACE2)是宿主细胞表面的一种进入受体,被认为对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的感染能力有害。自其爆发以来,科学家们一直在努力寻找治疗方法,但收效甚微。在这项研究中,我们评估了盐酸 5-氨基酮戊酸(ALA)抑制宿主细胞 ACE2 表达的潜力。进行了 ACE2 表达和 ALA 给药后细胞内卟啉的产生。我们观察到 ALA 给药后 ACE2 表达和细胞内卟啉减少。ALA 抑制宿主细胞中的 ACE2 表达,可能阻止 SARS-CoV-2 与宿主细胞结合。ALA 和硫酸亚铁(SFC)联合给药导致 ACE2 表达进一步降低和细胞内血红素水平增加。这表明 ALA 对 ACE2 表达的抑制可能通过血红素生成发生。我们发现,参与血红素降解的血红素加氧酶-1(HO-1)的抑制也导致 ACE2 表达降低,这表明 HO-1 在抑制 ACE2 方面可能发挥作用。总之,我们推测 ALA 与 SFC 联合给药可能通过抑制 ACE2 表达成为降低 SARS-CoV-2 感染性的潜在治疗方法。